Mice with either insufficient MYC or reduced ribosome biogenesis have a slower incidence of MYC driven lymphomas [38,39], and an inhibitor of RNA polymerase I transcription is in clinical trials in patients with hematological malignancies [40]. The gene discussed is MYC; the disease is hematologic disorder.